Histiocytic neoplasms: Going, going, but not quite gone.

BRAF and MEK inhibitors have revolutionised the treatment of patients with high-risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn? Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18964.